Lung Cancer News and Research

Latest Lung Cancer News and Research

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

Scientists discover key molecule that targets tumour blood vessels

Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Following the conclusion of a series of meetings with the United States Food and Drug Administration (FDA), GTx, Inc. announced today the clinical trial design for the two Phase III Ostarine registration studies for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC).

6 Jun 2011

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech, a member of the Roche Group, today announced results from OCEANS, a Phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer.

6 Jun 2011

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease.

6 Jun 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.

6 Jun 2011

Women with ovarian cancer do not benefit from CA-125 and transvaginal ultrasound

In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase in invasive medical procedures and associated harms as a result of being screened, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Genentech, a member of the Roche Group and Astellas Pharma US, Inc., today announced results of EURTAC, the first Phase III study with Tarceva in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC).

4 Jun 2011

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL from June 3 to June 7, 2011.

4 Jun 2011

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies.

3 Jun 2011

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

3 Jun 2011

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

Clovis Oncology, Inc. and Roche, announced today that they have entered into an agreement to develop an in vitro PCR based companion diagnostic test.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity.

2 Jun 2011

Five organizations receive IASLC travel awards to attend 14th World Conference on Lung Cancer

Five advocacy organizations from India, Australia and the United States have been granted travel awards by the International Association for the Study of Lung Cancer (IASLC) to send representatives to the 14th World Conference on Lung Cancer, July 3-7 in Amsterdam.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Lung Cancer News and Research

Latest Lung Cancer News and Research

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Scientists discover key molecule that targets tumour blood vessels

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Women with ovarian cancer do not benefit from CA-125 and transvaginal ultrasound

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Genentech, Astellas announce results of Tarceva Phase III study against advanced NSCLC

Response Genetics' clinical approaches to improve cancer care to be presented at ASCO 2011

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

Syndax receives U.S. patent for entinostat to treat metastatic cancers

Clovis Oncology, Roche partner to develop in vitro PCR-based diagnostic test for NSCLC

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Five organizations receive IASLC travel awards to attend 14th World Conference on Lung Cancer

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in